A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time

Hliniak, A; Gwiazdowska, B.; Szutkowski, Z.; Kraszewska, Ewa; Kukołowicz, Paweł; Jarząbski, A.; Sochacka, Boguslawa; Mazurkiewicz, Maria; Paprota, Krzysztof; Oliskiewicz, W; Zadrozna, O; Milecki, Piotr; Kubiak, Maria; Czopkiewicz, L.; Jagas, Maria; Góźdż, Stanisław; Wieczorek, Aleksandra; Woytowicz, A; Cisowska, B.; Magdziarz, H; Nowakowski, S.F.; Kośniewski, W.; Laskosz, I.; Serafin, Antonio; Gradon, E

doi:10.1016/s0167-8140(01)00494-7

Cited by 60 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was therefore obvious to attempt to minimize the time available for accelerated repopulation between the single fractions of radiotherapy simply by reducing the overall treatment time and keeping the same total dose and dose per fraction. This principle has lately shown the same beneficial trend in several large clinical studies [4,5]. Among these is the Danish DAHANCA 6 & 7 study, which compared 5 fx/wk with 6 fx/wk.…”

mentioning

confidence: 91%

The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma

et al. 2005

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 91%

The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Future research is required to investigate the longer term outcomes including late toxicity with comparison to the standard treatment (i.e. concurrent chemo-radiotherapy) [18][19][20][21][22][23][24][25][26][27][28][29][30][31]. …”

Section: Discussionmentioning

confidence: 99%

Accelerated Fractionation Radiotherapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma

Sakr¹

2017

JCPCR

View full text Add to dashboard Cite

Purpose: Acute toxicity, tumor control and survival outcomes were prospectively evaluated following accelerated fractionation radiotherapy for head and neck squamous cell carcinoma (HNSCC).Methods: Between 2012-2013, patients with non-metastatic HNSCC (T1-2N1 or T3-4N0-1) were accrued to a phase I/II prospective study. All patients were treated with 70 Gy in 30 fractions over 5 weeks (6 fractions/week). Acute toxicity, clinical response, local (LC), regional (RC) and distant control (DC), disease free-(DFS) and overall-survival (OS) were analyzed. Results:In total, 40 patients were enrolled; median follow-up was 41 months. The majority of patients were clinical stage III (n=37, 92.5%), ≥ 50 year (n=34, 85%), and male gender (n=29, 72.5%). Approximately half of the patients had laryngeal cancer. The overall grade 3 acute toxicity was 62.5%; mainly mucositis (n=23, 57.5%) and dysphagia (n=18, 45%). Overall, 34 patients (85%) showed complete response following radiotherapy. Three-year LC, RC, DC, OS and DFS were 81.6%, 85.3%, 90.3%, 64.4% and 58.7%, respectively. Conclusion:Our proposed accelerated fractionation radiotherapy regimen appears feasible and safe. Future research is required to investigate the longer term outcomes including late toxicity with comparison to the standard treatment (i.e. concurrent chemo-radiotherapy).

show abstract

“…Results in this group (group H -hypofractionated accelerated RT -KBN 6 P05C 032 20 project) were compared to results obtained in the trial that was conducted earlier in the same centers and used the same set of clinical data (group A -accelerated RT, 196 patients and group S -standard RT, 199 patients, KBN 4 3004 94C/2008 project). 20 …”

Section: Methodsmentioning

confidence: 99%

Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls

Szutkowski

Kawecki

Jarząbski

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time

Cited by 60 publications

References 9 publications

The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma

The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma

Accelerated Fractionation Radiotherapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma

Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls

Contact Info

Product

Resources

About